Using the PEG framework with analyst consensus forward EPS growth of 15.5%, Biogen Inc. has a fair value of $244.13 based on NTM EPS (FY2026) of $15.76. The current PEG ratio is 0.78.
PEG < 1 = bargain, 1–1.5 = fair, > 2 = expensive.
PEG is most informative for high-growth companies — the PEG sweet spot.
| EPS Growth RateForward | 15.5% |
| Adjusted Growth (clamped 8–25%) | 15.5% |
| Fair P/E | 15.5x |
| NTM EPS (FY2026) | $15.76 |
| Fair Value | $244.13 |
| Period | EPS Est. | Growth | Analysts |
|---|---|---|---|
| FY2025 (actual) | $8.83 | — | — |
| FY2026E | $15.76 | +78.5% | 30 |
| FY2027E | $16.18 | +2.7% | 29 |
| FY2028E | $17.34 | +7.2% | 24 |
| FY2029E | $17.96 | +3.6% | 23 |
| FY2030E | $18.14 | +1.0% | 15 |
5Y Forward EPS CAGR: 15.5%
| Year | Net Income | EPS | YoY |
|---|---|---|---|
| FY2021 | $1.6B | $10.40 | — |
| FY2022 | $3.0B | $20.87 | +100.7% |
| FY2023 | $1.2B | $7.97 | -61.8% |
| FY2024 | $1.6B | $11.19 | +40.4% |
| FY2025 | $1.3B | $8.83 | -21.1% |
4Y Historical EPS CAGR: -4.0%
The PEG Fair Value uses the Price/Earnings-to-Growth framework. A stock is fairly valued when its P/E ratio equals its earnings growth rate (PEG = 1.0). This model adds dividend yield to the growth rate per the original PEGY formula.
Growth rate priority: analyst consensus forward EPS CAGR (when ≥ 3 analysts cover the stock), falling back to historical EPS CAGR. Using EPS rather than net income avoids distortion from share buybacks. The growth rate is clamped between 8% and 25% — below 8% would undervalue stable earners, while above 25% would overvalue unsustainable spikes.